Prostate Cancer
Drug: ET 743 ( Yopndelis )
Phase II
Estimated Enrollment: 33
Study Start Date: June 2002
Estimated Study Completion Date: April 2008
Estimated Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)